Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$33.22

-0.96 (-2.81%)

07:53
04/18/19
04/18
07:53
04/18/19
07:53

Alkermes shares trading near base business value, says JPMorgan

Ahead of his conference call today with CEO Richard Pops, JPMorgan analyst Cory Kasimov says shares of Alkermes are trading near the company's base business value of $33 and that fundamental downside risk at these levels is "relatively limited." What is harder to determine is whether Alkermes shares will remain range bound for a prolonged period of time or if the company will start to get credit for its later stage product candidates, Kasimov tells investors in a research note. The analyst believes ALKS 3831 and Vumerity are "worth something at this juncture" and that improving investor sentiment will be key, along with solid execution in the near term, to unlock this potential value. He maintains an Overweight rating on Alkermes with a $41 price target.

  • 18

    Apr

ALKS Alkermes
$33.22

-0.96 (-2.81%)

04/09/19
PIPR
04/09/19
NO CHANGE
Target $32
PIPR
Neutral
Alkermes' ALPINE data an incremental positive, says Piper Jaffray
After Alkermes (ALKS) reported this morning that its ALPINE trial met its primary endpoint and that Aristada showed similar efficacy to the current market leader, Invega Sustenna, at all time points assessed, Piper Jaffray analyst Danielle Brill said she views the data as an incremental positive. However, she thinks it will be challenging to capture share from Johnson & Johnson (JNJ), telling investors that she is "not sure these data will be enough to move the needle." Brill maintains a Neutral rating on Alkermes.
04/12/19
GSCO
04/12/19
NO CHANGE
Target $27
GSCO
Sell
Goldman still thinks ALKS 3831 is 'unlikely to be practice changing'
After Alkermes presented additional details on efficacy and safety, as well as the first look at the metabolic data from the Enlighten-2 trial and interim data from the ongoing extension study, Goldman Sachs analyst Terence Flynn continues to believe the company's schizophrenia drug ALKS 3831 is "unlikely to be practice changing." The analyst reiterates a Sell rating on the shares with a $27 price target. ALKS 3831 demonstrated a comparable metabolic profile relative to Zyprexa over the 24-week portion of the trial, Flynn tells investors in a research note. The analyst believes an outstanding question remains with respect to potential long term type 2 diabetes risk. It is unclear if the existing ALKS 3831 data will be enough to drive a differentiated label for the drug versus Zyprexa in this regard, which could have commercial implications, says the analyst.
04/12/19
PIPR
04/12/19
NO CHANGE
Target $32
PIPR
Neutral
Alkermes' ALKS-3831 ph3 data saw negligible relative benefit, says Piper Jaffray
Piper Jaffray analyst Danielle Brill kept her Neutral rating and $32 price target on Alkermes after its Phase 3 schizophrenia trial data for ALKS-3831 presented at SIRS conference. The analyst says the results showed some "beneficial impacts on weight gain with '3831" when patients switched from olanzapine, but the benefit on metabolic parameters was negligible. Brill states that Alkermes management intends to file a new drug application for '3831 by mid-2019, and while she believes the data support approval, she questions the program's "overall commercial opportunity" relative to other available agents with "more benign safety profiles."
04/15/19
JEFF
04/15/19
NO CHANGE
Target $36
JEFF
Hold
ALKS 3831 could see initial use in olanzapine patients, says Jefferies
Jefferies analyst Biren Amin says the key opinion leaders he spoke to indicate ALKS 3831 could see initial use and uptake in patents already on olanzapine but that the drug's use will be limited. Key opinion leaders found the absolute four pound decrease at six months between the two treatment groups to be lacking, with a desire for a minimum of 10 pounds or greater in average weight decrease in patients that were on 3831 versus olanzapine, Amin tells investors in a research note. Further, regarding the drug's metabolic profile, since no change in lipid or glucose profile was observed and given that the study wasn't powered to detect a difference between treatment arms, the data was not considered meaningful by most opinion leaders, adds the analyst. His base case puts ALKS 3831 peak sales at $500M. Amin keeps a Hold rating on Alkermes with a $36 price target.

TODAY'S FREE FLY STORIES

KHC

Kraft Heinz

$31.59

-0.29 (-0.91%)

17:39
12/11/19
12/11
17:39
12/11/19
17:39
Initiation
Kraft Heinz initiated  »

Kraft Heinz resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

K

Kellogg

$66.17

-0.48 (-0.72%)

17:37
12/11/19
12/11
17:37
12/11/19
17:37
Initiation
Kellogg initiated  »

Kellogg resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.32

-0.085 (-0.59%)

17:34
12/11/19
12/11
17:34
12/11/19
17:34
Hot Stocks
UAW ratifies CBA with Fiat Chrysler »

UAW Fiat Chrysler U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

FLO

Flowers Foods

$21.54

-0.04 (-0.19%)

17:27
12/11/19
12/11
17:27
12/11/19
17:27
Initiation
Flowers Foods initiated  »

Flowers Foods resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:25
12/11/19
12/11
17:25
12/11/19
17:25
General news
U.S. Treasury posted a -$208.8 B budget deficit in November »

U.S. Treasury posted a…

NOMD

Nomad Foods

$20.54

-0.12 (-0.58%)

17:23
12/11/19
12/11
17:23
12/11/19
17:23
Initiation
Nomad Foods initiated  »

Nomad Foods resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMPX

LMP Automotive

$15.05

1.75 (13.16%)

17:23
12/11/19
12/11
17:23
12/11/19
17:23
Hot Stocks
LMP Automotive Chairman Samer Tawfik buys over $1.7M in company shares »

LMP Automotive Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$28.91

0.1 (0.35%)

17:21
12/11/19
12/11
17:21
12/11/19
17:21
Syndicate
Breaking Syndicate news story on Triumph Group »

Triumph Group files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKC

McCormick

$170.70

-0.635 (-0.37%)

17:12
12/11/19
12/11
17:12
12/11/19
17:12
Initiation
McCormick initiated  »

McCormick resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$33.37

0.27 (0.82%)

17:10
12/11/19
12/11
17:10
12/11/19
17:10
Conference/Events
Continental Resources to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$51.57

-1.67 (-3.14%)

, K

Kellogg

$66.17

-0.48 (-0.72%)

17:08
12/11/19
12/11
17:08
12/11/19
17:08
Initiation
General Mills, Kellogg initiated  »

General Mills resumed…

GIS

General Mills

$51.57

-1.67 (-3.14%)

K

Kellogg

$66.17

-0.48 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CEI

Camber Energy

$2.05

0.86 (72.27%)

17:05
12/11/19
12/11
17:05
12/11/19
17:05
Hot Stocks
Camber Energy responds to unusual market activity »

Camber Energy commented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$0.69

0.0554 (8.73%)

17:04
12/11/19
12/11
17:04
12/11/19
17:04
Conference/Events
Miragen Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGI

Alamos Gold

$5.57

0.205 (3.82%)

17:03
12/11/19
12/11
17:03
12/11/19
17:03
Hot Stocks
Alamos Gold sees FY20 production 425K-465K ounces of gold »

Alamos Gold provided 2020…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMNFF

MedMen

$0.00

(0.00%)

17:02
12/11/19
12/11
17:02
12/11/19
17:02
Earnings
MedMen sees positive adjusted EBITDA in Q121, and positive FCF in Q321 »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CPB

Campbell Soup

$48.00

-0.37 (-0.76%)

17:02
12/11/19
12/11
17:02
12/11/19
17:02
Initiation
Campbell Soup initiated  »

Campbell Soup resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMNFF

MedMen

$0.00

(0.00%)

17:00
12/11/19
12/11
17:00
12/11/19
17:00
Earnings
MedMen sees FY20 revenue $225M - $245M, consensus $212.69M »

Sees FY21 revenue $450 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

XOM

Exxon Mobil

$68.95

-0.11 (-0.16%)

16:59
12/11/19
12/11
16:59
12/11/19
16:59
Hot Stocks
Exxon Mobil's Milton sells 13,569 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SJM

J.M. Smucker

$104.42

-1.64 (-1.55%)

16:57
12/11/19
12/11
16:57
12/11/19
16:57
Initiation
J.M. Smucker initiated  »

J.M. Smucker resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

16:55
12/11/19
12/11
16:55
12/11/19
16:55
Conference/Events
Oppenheimer healthcare analysts to hold a KOL dinner meeting »

Analysts hold a Cardiac…

MMNFF

MedMen

$0.00

(0.00%)

16:54
12/11/19
12/11
16:54
12/11/19
16:54
Hot Stocks
MedMen granted delivery-only license by the city of Mountain View, California »

On November 21, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CAG

Conagra Brands

$28.64

-0.58 (-1.98%)

16:53
12/11/19
12/11
16:53
12/11/19
16:53
Initiation
Conagra Brands initiated  »

Conagra Brands resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

EQH

AXA Equitable

$24.27

-0.18 (-0.74%)

16:53
12/11/19
12/11
16:53
12/11/19
16:53
Hot Stocks
AXA Equitable sells two run-off and closed-block companies »

AXA Equitable has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

MMNFF

MedMen

$0.00

(0.00%)

16:50
12/11/19
12/11
16:50
12/11/19
16:50
Hot Stocks
MedMen announces financial updates to strengthen balance sheet »

MedMen Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

MDLZ

Mondelez

$53.94

-0.13 (-0.24%)

16:48
12/11/19
12/11
16:48
12/11/19
16:48
Initiation
Mondelez initiated  »

Mondelez resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.